Trial reportNeuro-oncology2022
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study.
Trial report in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- A systematic review and meta-analysis of x-ray therapy versus proton beam therapy for pediatric central nervous system germ cell tumors: TRP-Germinoma 2025.International journal of clinical oncology · 2025Pooled it
- Phase II trial of pathology-based tripartite treatment stratification for patients with CNS germ cell tumors: A long-term follow-up study.Neuro-oncology · 2025Trial
- Intracranial Germ Cell Tumors: An Updated Review of Diagnostic Strategies and Treatment Paradigms.Asian journal of neurosurgery · 2026Review
- Germinoma in late adulthood with extensive dissemination: a case report and literature review.Brain tumor pathology · 2026Article
- Final report of the SIOP-CNS-GCT II protocol for germinoma: Omitting radiotherapy boost is safe in localized disease in complete remission after chemotherapy.Neuro-oncology · 2026Article
- Comprehensive characterization and prognostic analysis of multifocal intracranial germ cell tumors.BMC neurology · 2026Article
- Long-term intelligence after high-dose radiotherapy to the primary site versus chemotherapy and whole-ventricle radiotherapy in patients with germinoma.International journal of clinical oncology · 2026Article
- Crosstalk of cancer stemness-neutrophils in outcome of intracranial germ cell tumors.Frontiers in immunology · 2026Article
- The potential and risks of FLASH radiotherapy in pediatric patients.Neuro-oncology pediatrics · 2026Review
- Long-term trends and disparities in primary intracranial germ cell tumor incidence and mortality for child and adolescent in the USA.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Old Tools in a New Era: The Continued Relevance of Chemotherapy in Pediatric Neuro-Oncology.Current oncology (Toronto, Ont.) · 2025Review
- Comparison of treatment outcomes between combined chemotherapy-radiation therapy (chemo-RT) and radiation therapy alone (RT) for intracranial germ cell tumors in adolescent and young adult patients (AYA).Discover oncology · 2025Article
- Pediatric CNS Radiation Oncology: Recent Developments and Novel Techniques.Current oncology (Toronto, Ont.) · 2025Review
- Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions.Neuro-oncology · 2025Review
- Intracranial germ cell tumors: advancement in genomic diagnostics and the need for novel therapeutics.Frontiers in oncology · 2025Review
- Intracranial lobar germinoma presenting with refractory hypernatremia.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Article
- High detection rate of circulating-tumor DNA from cerebrospinal fluid of children with central nervous system germ cell tumors.Acta neuropathologica communications · 2024Article
- Risk-Stratified Radiotherapy in Pediatric Cancer.Cancers · 2024Review
- Novel molecular subtypes of intracranial germ cell tumors expand therapeutic opportunities.Neuro-oncology · 2024Article
- Panhypopituitarism caused by a suprasellar germinoma: A case report.World journal of clinical cases · 2024Article
Corrections and comments
- Commented on by
Authors and funding
18 authors at 14 institutions in 2 countries.
Funding
Abstract
backgroundThe study aimed to evaluate whether simplified chemotherapy followed by dose-reduced irradiation was effective for treating patients (ages 3-21 years) with localized germinoma. The primary endpoint was 3-year progression-free survival (PFS) rate.
methodsPatients with a complete response to chemotherapy with carboplatin and etoposide received 18 Gy WVI + 12 Gy boost to the tumor bed. Patients with partial response proceeded to 24 Gy WVI + 12 Gy. Longitudinal cognitive functioning was evaluated prospectively on ALTE07C1 and was a primary study aim.
resultsOne hundred and fifty-one patients were enrolled; 137 were eligible. Among 90 evaluable patients, 74 were treated with 18 Gy and 16 with 24 Gy WVI. The study failed to demonstrate noninferiority of the 18 Gy WVI regimen compared to the design threshold of 95% 3-year PFS rate, where, per design, patients who could not be assessed for progression at 3 years were counted as failures. The Kaplan-Meier (KM)-based 3-year PFS estimates were 94.5 ± 2.7% and 93.75 ± 6.1% for the 18 Gy and 24 Gy WVI cohorts, respectively. Collectively, estimated mean IQ and attention/concentration were within normal range. A lower mean attention score was observed at 9 months for patients treated with 24 Gy. Acute effects in processing speed were observed in the 18 Gy cohort at 9 months which improved at 30-month assessment.
conclusionsWhile a failure according to the prospective statistical noninferiority design, this study demonstrated high rates of chemotherapy responses, favorable KM-based PFS and OS estimates in the context of reduced irradiation doses and holds promise for lower long-term morbidities for patients with germinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.